Vanda Pharmaceuticals (VNDA) Interest Expenses (2010 - 2026)

Vanda Pharmaceuticals (VNDA) has 17 years of Interest Expenses data on file, last reported at $7.9 million in Q1 2026.

• For the quarter ending Q1 2026, Interest Expenses rose 13.43% year-over-year to $7.9 million; the trailing twelve-month figure through Mar 2026 stood at $7.9 million (up 13.43% YoY), and the FY2025 full-year result was $124.4 million, up 1299.81% from the prior year.
• Interest Expenses improved to $7.9 million in Q1 2026, from $2.7 million in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $8.9 million in Q4 2024 to a low of $1.5 million in Q3 2023.
• A 5-year average of $5.3 million and a median of $7.0 million in 2024 frame the typical range for Interest Expenses.
• Across the five-year window, Interest Expenses sank 91.56% in 2022 and jumped 378.95% in 2024, its largest moves.
• Tracing VNDA's Interest Expenses over 5 years: stood at $7.1 million in 2022, then grew by 19.77% to $8.5 million in 2023, then rose by 3.98% to $8.9 million in 2024, then sank by 69.64% to $2.7 million in 2025, then soared by 194.59% to $7.9 million in 2026.
• Business Quant data shows VNDA's Interest Expenses at $7.9 million in Q1 2026, $2.7 million in Q4 2025, and $7.0 million in Q3 2025.